Pacira BioSciences Reports Second Quarter 2020 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Pacira Pharma (PCRX) Tops Q2 EPS by 3c, Revenues Beat
August 6, 2020 8:04 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.12, $0.03 better than the analyst estimate of $0.09. Revenue for the quarter came in at $75.51 million versus the consensus estimate of $72.46 million.
Second Quarter 2020 Financial Results
Total revenues were $75.5 million in the second quarter of 2020, a 26% decrease versus the $102.6 million reported for the second... More